z-logo
Premium
Myeloid expression of the AP ‐1 transcription factor JUNB modulates outcomes of type 1 and type 2 parasitic infections
Author(s) -
Fontana M. F.,
Baccarella A.,
Kellar D.,
Oniskey T. K.,
Terinate P.,
Rosenberg S. D.,
Huang E. J.,
Herbert D. R.,
Kim C. C.
Publication year - 2015
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12215
Subject(s) - junb , biology , immunology , myeloid , immune system , cytokine , transcription factor , fosb , chemokine , cancer research , biochemistry , gene
Summary Activation of macrophages is a key step in the initiation of immune responses, but the transcriptional mechanisms governing macrophage activation during infection are not fully understood. It was recently shown that the AP ‐1 family transcription factor JUNB positively regulates macrophage activation in response to Toll‐like receptor agonists that promote classical or M1 polarization, as well as to the cytokine interleukin‐4 ( IL ‐4), which elicits an alternatively activated or M2 phenotype. However, a role for JUNB in macrophage activation has never been demonstrated in vivo . Here, to dissect the role of JUNB in macrophage activation in a physiological setting, mice lacking JUNB specifically in myeloid cells were tested in two infection models: experimental cerebral malaria, which elicits a pathological type 1 immune response, and helminth infection, in which type 2 responses are protective. Myeloid‐restricted deletion of Junb reduced type 1 immune activation, which was associated with reduced cerebral pathology and improved survival during infection with Plasmodium berghei . Myeloid JUNB deficiency also compromised type 2 activation during infection with the hookworm Nippostrongylus brasiliensis , leading to diminished cytokine production and eosinophil recruitment and increased parasite burden. These results demonstrate that JUNB in myeloid cells shapes host responses and outcomes during type 1 and type 2 infections.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here